A University of Virginia (UVA) researcher has secured a federal grant to advance the study of rare circulating cells, aiming to improve how clinicians detect and analyze disease at the cellular level. Assistant Professor of Biomedical Engineering Dr. Jason Papin and his team received funding from the National Institutes of Health (NIH) to develop specialized microfluidic technologies designed to isolate these elusive cells from blood samples, according to an official university announcement.
Advancing Rare Cell Detection Technologies
The core of this research focuses on circulating tumor cells (CTCs) and other rare cells that are often present in miniscule quantities within the bloodstream. According to the National Cancer Institute (NCI), detecting these cells is difficult because they are frequently outnumbered by millions of healthy blood cells. The UVA project aims to refine microfluidic “lab-on-a-chip” devices that use physical and biochemical markers to capture these cells more efficiently than current clinical standards.
By improving the sensitivity of these diagnostic tools, the team hopes to enable earlier intervention for patients. The research builds on existing methodologies for liquid biopsies, which allow for less invasive monitoring of cancer progression compared to traditional tissue biopsies. The NIH-funded project is expected to run over several years, with the goal of translating these laboratory prototypes into scalable clinical tools.
Why Circulating Cells Matter for Clinical Diagnosis
Circulating cells provide a real-time “snapshot” of a patient’s health, particularly in oncology. When cells detach from a primary tumor and enter the circulatory system, they can provide genetic information about the cancer’s mutations. According to the American Cancer Society, studying these cells can help physicians select more targeted, personalized therapies for patients, as the genetic profile of circulating cells may differ from the primary tumor site.
Beyond cancer, this technology has potential applications in identifying fetal cells in maternal blood or detecting signs of transplant rejection. The focus of the UVA team remains on optimizing the capture rate while maintaining the integrity of the cells, which is essential for accurate downstream genomic sequencing.
Project Timeline and Research Objectives
The grant, awarded through the National Institute of Biomedical Imaging and Bioengineering (NIBIB), supports the development phase of the technology. The research objectives include:
- Device Optimization: Designing microfluidic channels that reduce cellular stress during the isolation process.
- Validation Studies: Testing the efficacy of the capture system using clinical blood samples to ensure accuracy in complex biological environments.
- Scalability Assessment: Evaluating how these tools can be integrated into high-throughput laboratory workflows.
The team is currently working to finalize the prototype designs. As the study progresses, the findings will be submitted for peer review in medical and engineering journals to validate the clinical utility of the devices.
Frequently Asked Questions
What is a liquid biopsy?
A liquid biopsy is a test performed on a sample of blood to look for cancer cells or pieces of DNA from tumor cells that are circulating in the blood, as defined by the National Cancer Institute.
How do microfluidic devices work for cell capture?
These devices use microscopic channels to manipulate fluids at a very small scale. By coating these channels with specific antibodies or using physical properties like cell size, the devices can trap rare cells while allowing common blood cells to pass through.
When will this technology be available for patients?
The current project is in the research and development phase. Clinical availability depends on successful validation studies and subsequent regulatory review by the U.S. Food and Drug Administration (FDA).
Related reading